Enzyme News and Research

RSS

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

Recent research suggests vitamin D may be able to stop or prevent cancer. Now, a new study finds an enzyme that plays a role in metabolizing vitamin D can predict lung cancer survival.

1 Mar 2011

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

Bristol-Myers Squibb announced today that BARACLUDE(R) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B in adult patients with evidence of decompensated liver disease.

1 Mar 2011

FDA approves roflumilast to treat COPD

The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups or worsening of symptoms from severe chronic obstructive pulmonary disease.

1 Mar 2011

New drug approved for COPD by the FDA

The U.S. FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD). COPD affects smokers and the elderly and leads to severe difficulty in breathing, chronic cough and excessive mucus production. An exacerbation can last up to several weeks and result in a decline in lung function and increased risk of death, and it may be associated with severe anxiety, the FDA says.

1 Mar 2011

Gut bacteria could exert control over metabolic functions of other organs

Bacteria in the human gut may not just be helping digest food but also could be exerting some level of control over the metabolic functions of other organs, like the liver, according to research published this week in the online journal mBio-. These findings offer new understanding of the symbiotic relationship between humans and their gut microbes and how changes to the microbiota can impact overall health.

1 Mar 2011

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Sanfilippo disease is a rare disorder caused by the failure of enzymes to break down specific kinds of complex carbohydrates, resulting in their accumulation in cells and often severe physical and neurological problems - and sometimes early death.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Synageva supports Fourth International Rare Disease Day

Synageva BioPharma Corp., a privately held biopharmaceutical company that is developing therapeutic products for rare disorders, announced today that the company is supporting the Fourth International Rare Disease Day observance on February 28, 2011.

28 Feb 2011

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Just in time for Heart Health Month, EcoNugenics introduces CIRCUTOL Cardiovascular Health Support. EcoNugenics has once again demonstrated excellence in being at the forefront of the latest developments in natural alternative health solutions.

28 Feb 2011

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Researchers at the University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego say an evolutionary gene mutation that occurred in human millions of years ago and our subsequent inability to produce a specific kind of sugar molecule appears to make people more vulnerable to developing type 2 diabetes, especially if they're overweight.

25 Feb 2011

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.

25 Feb 2011

FN-EDA protein can reduce damage after heart attack

Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

25 Feb 2011

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

As if the recent prediction that half of all Americans will have diabetes or pre-diabetes by the year 2020 isn't alarming enough, a new genetic discovery published online in the FASEB Journal provides a disturbing explanation as to why: we took an evolutionary "wrong turn."

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Stereotaxis reports first-ever use of Niobe Magnetic Navigation System to treat hypertension

Stereotaxis, Inc. announced today the first-ever use of its Niobe® Magnetic Navigation System in a renal artery ablation procedure for the treatment of chronic hypertension that was not treatable with medication.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Enzyme News and Research

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

New study: Enzyme that metabolizes vitamin D can predict lung cancer survival

European Commission approves BMY's BARACLUDE(r) to treat CHB in adult patients with liver disease

FDA approves roflumilast to treat COPD

New drug approved for COPD by the FDA

Gut bacteria could exert control over metabolic functions of other organs

New personalized therapy fools cancer cells into killing themselves

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

TCD announces first patient treated in its TCD-717 Phase I trial

Synageva supports Fourth International Rare Disease Day

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

FN-EDA protein can reduce damage after heart attack

Research: Loss of CMAH's function may make humans more prone to obesity and diabetes

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Stereotaxis reports first-ever use of Niobe Magnetic Navigation System to treat hypertension

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Antiepileptic drugs could make HIV drugs less effective

Biochemistry eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News